In pancreatic cancer cells, withaferin A disrupts the Hsp90–Cdc37 interaction, while it neither blocks ATP binding to Hsp90 nor disrupts the Hsp90–p23 interaction [77]. This evidence concerns the gene CDC37 and pancreatic neoplasm.